Dual targeting of solid lipid nanoparticles grafted with 83-14 MAb and anti-EGF receptor for malignant brain tumor therapy

Life Sciences
Yung-Chih Kuo, Chia-Hao Lee

Abstract

Solid lipid nanoparticles (SLNs) conjugated with surface 83-14 monoclonal antibody (8314MAb) and anti-epithelial growth factor receptor (AEGFR) were synthesized and applied to permeate the blood-brain barrier (BBB) and inhibit the growth of glioblastoma multiforme (GBM). 8314MAb and AEGFR were crosslinked on SLNs to carry etoposide (ETP) across human brain-microvascular endothelial cells (HBMECs) and to treat U87MG cells. An increase in the 8314MAb concentration increased the permeability for propidium iodide (PI) and ETP across the BBB, however, decreased the 8314MAb grafting efficiency and transendothelial electrical resistance of the monolayer of HBMECs. In addition, an increase in the AEGFR concentration enhanced the viability of HBMECs and human astrocytes (HAs), however, reduced the AEGFR grafting efficiency and ETP release rate. An incorporation of both 8314MAb and AEGFR increased the particle size, however, decreased the zeta potential, ETP release rate, and viability of HBMECs and HAs. The conjugation of 8314MAb and AEGFR on ETP-loaded SLNs can be a promising strategy to deliver antitumor ETP to the brain and restrain the propagation of GBM.

References

Jan 1, 1984·Cancer Drug Delivery·M K SpigelmanJ F Holland
Dec 5, 2000·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·P J Gaillard, A G de Boer
May 5, 2001·Brain Research. Brain Research Reviews·M Bredel
Oct 13, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J Baselga
Apr 9, 2004·Nature Reviews. Molecular Cell Biology·Elisabetta Dejana
Aug 11, 2004·Toxicon : Official Journal of the International Society on Toxinology·M GordalizaM A Gómez-Zurita
Sep 27, 2005·Veterinary Immunology and Immunopathology·Nicola F FletcherJohn J Callanan
Sep 12, 2006·Annual Review of Pharmacology and Toxicology·A G de Boer, P J Gaillard
Apr 21, 2007·Biomacromolecules·Federica RusminiJan Feijen
Jun 5, 2007·Advanced Drug Delivery Reviews·António J Almeida, Eliana Souto
Jun 8, 2007·Pharmaceutical Research·William M Pardridge
Jul 11, 2007·Pharmaceutical Research·Angela R Jones, Eric V Shusta
Jul 27, 2007·Chemistry and Physics of Lipids·Katarzyna Hac-Wydro, Paweł Wydro
Jul 8, 2008·Critical Reviews in Oncology/hematology·Andreas A ArgyriouHaralabos P Kalofonos
Aug 2, 2008·The New England Journal of Medicine·Patrick Y Wen, Santosh Kesari
Oct 24, 2008·The New England Journal of Medicine·Bruce R Bistrian
Apr 23, 2009·Advanced Drug Delivery Reviews·Clinton F Jones, David W Grainger
Aug 4, 2009·Research in Veterinary Science·Shaoyong LiWenzhong Zhou
Oct 20, 2009·Trends in Pharmacological Sciences·Yogeshkumar MalamAlexander M Seifalian
Feb 4, 2010·PLoS Genetics·Michael James ClarkStanley F Nelson
Nov 26, 2010·Journal of Controlled Release : Official Journal of the Controlled Release Society·Arehalli S ManjappaRayasa S Ramachandra Murthy
Jan 5, 2011·Colloids and Surfaces. B, Biointerfaces·Yung-Chih Kuo, Jui-Fang Chung
Apr 29, 2011·Colloids and Surfaces. B, Biointerfaces·Yung-Chih Kuo, Chin-Hsun Lu
Jun 4, 2011·Colloids and Surfaces. B, Biointerfaces·Yung-Chih Kuo, Chin-Hsun Lu
Jul 26, 2011·Annals of Neurology·Matthias PreusserRoger Stupp
Dec 6, 2011·Colloids and Surfaces. B, Biointerfaces·Yung-Chih Kuo, Chin-Hsun Lu

❮ Previous
Next ❯

Citations

Aug 16, 2016·Materials Science & Engineering. C, Materials for Biological Applications·Małgorzata Geszke-Moritz, Michał Moritz
Jul 28, 2016·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Jianing MengIbrahima Youm
Feb 1, 2020·Expert Opinion on Therapeutic Patents·Rishi PaliwalMukesh Kumar Sahu
Dec 17, 2020·Pharmaceutics·Sathishbabu ParanthamanDevegowda Vishakante Gowda
Nov 17, 2020·Frontiers in Molecular Biosciences·Sebastián Scioli MontotoMaría Esperanza Ruiz
Feb 9, 2021·Expert Review of Clinical Pharmacology·Yadollah OmidiHossein Omidian
Jun 7, 2021·International Journal of Pharmaceutics·Marcela Tavares LuizMarlus Chorilli
Jan 23, 2020·Current Medicinal Chemistry·Amanda Letícia Polli SilvestreMarlus Chorilli
Nov 15, 2020·International Journal of Pharmaceutics·Elias da Silva SantosJosimar O Eloy

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Blood Brain Barrier Regulation in Health & Disease

The blood brain barrier is essential in regulating the movement of molecules and substances in and out of the brain. Disruption to the blood brain barrier and changes in permeability allow pathogens and inflammatory molecules to cross the barrier and may play a part in the pathogenesis of neurodegenerative disorders. Here is the latest research in this field.

Astrocytes

Astrocytes are glial cells that support the blood-brain barrier, facilitate neurotransmission, provide nutrients to neurons, and help repair damaged nervous tissues. Here is the latest research.